Guardant Health prelim FY22 revenue $447-450M, up 20%; test volumes up >40% YoY

Guardant Health, Inc.

2022-FY EPS reported -$6.41 revenue$449,538,000

Preliminary FY22 revenue $447M-$450M, up 20% YoY; Q4 revenue $124M-$127M, up 15-17%.
FY22 clinical test volumes 124,800 (+42% YoY); biopharma tests 26,000 (+40% YoY).
Q4 clinical tests 36,000 (+41% YoY); biopharma tests 8,200 (+24% YoY).
Cash, equivalents and marketable debt securities $1.0B as of Dec 31, 2022.
Positive ECLIPSE trial readout for Shield blood-based colorectal cancer test; expanding to lung cancer.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Guardant Health, Inc. reported the year ended December 31, 2022 results: revenue between $447 million and $450 million.

Period: the year ended December 31, 2022
Revenue: between $447 million and $450 million
Result: preliminary results

Exact text from the filing

Full year 2022 preliminary unaudited financial results For the twelve-month period ended December 31, 2022, as compared to the same period of 2021: • Revenue of between $447 million and $450 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Guardant Health, Inc. reported the quarter ended December 31, 2022 results: revenue between $124 million and $127 million.

Period: the quarter ended December 31, 2022
Revenue: between $124 million and $127 million
Result: preliminary results

Exact text from the filing

Fourth quarter 2022 preliminary unaudited financial results For the three-month period ended December 31, 2022, as compared to the same period of 2021: • Revenue of between $124 million and $127 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Guardant Health, Inc. filing history →

Source: SEC EDGAR

accession 0001576280-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.